Eslicarbazepine acetate

(Aptiom®)

Aptiom®

Latest News

loading GIF

Drug updated on 6/11/2024

Dosage FormTablet (oral; 200 mg, 400 mg, 600 mg, 800 mg)
Drug ClassAnticonvulsants
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Eslicarbazepine acetate (Aptiom) is indicated for the treatment of partial-onset seizures in patients 4 years of age and older, demonstrating efficacy in decreasing seizure frequency from baseline when compared to other antiseizure medications such as brivaracetam, cenobamate, lacosamide, and perampanel.
  • The information was derived from a total of 8 systematic reviews/meta-analyses studies that provided comprehensive insights into eslicarbazepine acetate's comparative effectiveness and safety across various populations.
  • In comparison with placebo treatments during network meta-analysis settings, eslicarbazepine acetate showed significantly higher efficacy in controlling seizures with fewer adverse events reported.
  • For adults with focal-onset epilepsy specifically, eslicarbazepine acetate demonstrated dose-dependent efficacy where an 800 mg/d dose was effective without significantly increasing severe adverse events unlike the larger dosage of 1,200 mg/d which raised incidence rates.
  • When considering pediatric populations suffering from drug-resistant focal-onset seizures, levetiracetam ranked highest for efficacy, while further evaluation is needed to clarify the relative efficacy of eslicarbazepine acetate within this subgroup.
  • An analysis including cenobamate against a cohort including eslicarbazepine acetate suggested that although cenobamate may be more efficacious overall, Aptiom remains a viable option particularly when balancing both its effectiveness alongside tolerability considerations.

Product Monograph / Prescribing Information

Document TitleYearSource
Aptiom (eslicarbazepine acetate) Prescribing Information.2019Sunovion Pharmaceuticals Inc. Marlborough, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines